Monte Rosa Therapeutics, Inc. (GLUE) Earnings
Monte Rosa Therapeutics, Inc. is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $-0.37. GLUE has beaten EPS estimates in 9 of its last 12 reported quarters (average surprise -11.8% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.28 | $-0.45 | -60.7% | $4M | -61.7% |
| Mar 17, 2026 | $-0.35 | $-0.54 | -53.6% | $3M | -82.0% |
| Nov 6, 2025 | $-0.39 | $-0.33 | +15.4% | $13M | -17.7% |
| Aug 7, 2025 | $-0.31 | $-0.15 | +51.6% | $23M | +198.4% |
| May 8, 2025 | $-0.24 | $0.57 | +337.5% | $85M | +526.0% |
| Mar 20, 2025 | $-0.37 | $0.23 | +162.2% | $61M | +30.0% |
| Nov 7, 2024 | $-0.45 | $-0.29 | +35.6% | $9M | +249.3% |
| Aug 8, 2024 | $-0.50 | $-0.43 | +14.0% | $5M | +248.1% |
| May 9, 2024 | $-0.56 | $-0.53 | +5.4% | $1M | -24.0% |
| Mar 14, 2024 | $-0.57 | $-0.58 | -1.8% | $9M | +148.1% |
| Nov 9, 2023 | $-0.75 | $-0.70 | +6.7% | — | — |
| Aug 10, 2023 | $-0.72 | $-0.71 | +1.4% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2024 · March 20, 2025
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• I&I Program: - Phase 1 study of MRT-6160 in healthy volunteers supports broad Phase 2 development, with dose-dependent VAV1 degradation and cytokine modulation. - NEK7 program on track for IND submission in H1 2025, with preclinical data showing potent NEK7 degradation and favorable safety. - Use of clean platform to expand oral I&I drug portfolio. • Oncology Program: - MRT-2359 Phase 1/2 study in castration-resistant prostate cancer shows early response in heavily pretreated patients, leading to focus on this indication. - Preclinical data for CDK2 and cyclin E1 programs show promising tumor regression in models.
Guidance
• MRT-6160: On track for broad Phase 2 development based on Phase 1 data. • NEK7: IND submission expected in H1 2025, with Phase 1 proof of concept planned in pericarditis and other cardioimmunology indications. • Cell cycle programs: IND submission expected in 2026. • Cash runway: Anticipated into 2028 with strong balance sheet.
Segment performance
The transcript focuses on the I&I and Oncology segments. In the I&I space, the Phase 1 healthy volunteer study of MRT-6160 showed dose-dependent VAV1 degradation exceeding 90% in T and B cells, with significant functional inhibition of cytokines. The NEK7 program is on track for an IND submission in H1 2025, with preclinical data demonstrating potent NEK7 degradation and favorable safety. In Oncology, the MRT-2359 Phase 1/2 study in castration-resistant prostate cancer showed early signs of clinical response in heavily pretreated patients. Preclinical data for CDK2 and cyclin E1 programs showed promising tumor regression in models.
Risks & headwinds
• Uncertainty in biomarker positivity affecting trial enrollment in certain cancer cohorts. • Potential infection risks with VAV1 program, though preclinical data shows favorable safety. • Discrepancies between preclinical and clinical biomarker data in some cancer indications.
Analyst Q&A
Q: How did you decide on the most promising indications for VAV1 with your partner?
A: Final decisions on Phase 2 studies not made yet, but preclinical data in UC, RA, and other T/B cell-related diseases inform potential indications.
Q: What level of VAV1 degradation do you expect in I&I patients based on ex vivo results?
A: Encouraging results from healthy volunteer trial suggest in vivo inhibition should match benchmark data, though exact percentage depends on disease and tissue.
Q: How are you thinking about the MYC biomarker in the breast cancer cohort for MRT-2359?
A: c-MYC high expression is widespread in breast cancer, similar to prostate cancer, with no need for companion diagnostics, but data from this cohort is lagging.
Q: What level of NEK7 degradation is needed for efficacy?
A: Aim for at least 80% degradation, as seen in ex vivo assays which show near 100% inhibition of IL-1 beta secretion at this level.
Q: Why plan Phase 1 proof of concept in pericarditis for NEK7?
A: Pericarditis is an indication with a well-defined development pathway within the broader cardioimmunology space, making it a logical starting point.